Container (Container)
Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 55111-302
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 55111-302). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Dr. Reddys Laboratories Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Graph1 (Graph1)
This appears to be a table or graph displaying changes in ADAS-cog (Alzheimer's Disease Assessment Scale - cognitive subscale) scores from baseline over the course of a drug treatment. The drug being evaluated is donepezil, with both 5mg/day and 10mg/day doses being tested, along with a placebo. The data appears to be broken down by weeks of treatment (6, 12, and 18), and includes values for clinical improvement and decline. There is no additional context provided.*
Graph10 (Graph10)
Graph11 (Graph11)
Graph12 (Graph12)
Graph13 (Graph13)
This text appears to be a table displaying the conversion of a dose of Donepezil from 10mg per day to 23mg per day, with some additional data points and a rating scale labeled as CIBIC-plus. It is difficult to determine the context and purpose of this data without additional information.*
Graph2 (Graph2)
The text describes a chart showing the cumulative percentage of patients for Donepezil 10 mg/day, Donepezil 5 mg/day, and Placebo. There is also a graph showing the change in ADAS cog, with treatment groups indicated. The percentages for patients on Donepezil 10 mg/day and Donepezil 5 mg/day are provided for certain measure points. The graph also shows the change from baseline on a scale of 0 to 15.*
Graph3 (Graph3)
This appears to be a chart or graph showing the percentage of patients in different treatment groups (Donepezil 10 mg/day, Donepezil 5 mg/day, and Placebo) evaluated by the CIBIC-plus Rating. The rating scale ranges from "Markedly Improved" to "Markedly Worse" with varying levels of improvement or change in between.*
Graph4 (Graph4)
Graph5 (Graph5)
This is a table showing the cumulative percentage of patients in a treatment group for a study on the effects of Donepezil on Alzheimer's disease. The table also includes changes in ADAS-cog scores for patients taking different doses of Donepezil versus a placebo. There are three treatment groups: Donepezil 10mg/day, Donepezil 5mg/day, and Placebo. The table shows the percentage change in ADAS-cog scores for each group at three different time points: baseline, 4 points, and 7 points.*
Graph6 (Graph6)
This appears to be a prescription dosage information for Donepezil, a medication commonly used to treat Alzheimer's disease. It includes dosing information for both 5mg and 10mg daily pills. The last line mentions a "CIBIC-plus rating", which is a standardized measurement used to assess the severity of cognitive decline in Alzheimer's patients.*
Graph7 (Graph7)
Graph8 (Graph8)
The text represents a comparison of clinical trial data between the drug Donepezil (administered at a dosage of 10mg/day) and a placebo. The data presented in the table measures SIB (Severe Impairment Battery) change from baseline over a period of time, but the table is not readable due to poor formatting and lack of context.*
Graph9 (Graph9)
Structure (Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
